受国际权威法律评级机构钱伯斯（Chambers and Partners）邀请，环球律师事务所已连续第四年为其独家撰写
《全球法律指南：数字健康2024》之中国篇（法律与实践）
。该指南中各个国家与地区的章节均由钱伯斯排名中该专业领域的领先律所撰写，旨在简明扼要地介绍各司法辖区内该专业领域法律和实务的最新发展和趋势。
您可点击文末“阅读全文”，下载《数字健康2024》PDF版全文。
Chambers and Partners, one of the most authoritative international legal ranking agencies, invited Global Law Office and team to contribute for the fourth consecutive year to the
Chambers Global Practice Guide: Digital Healthcare 2024 China (Law & Practice)
. The China chapter is one of the individual chapters of the Chambers Global Practice Guide Series, with each being exclusively authored by leading firms in their respective fields, as ranked by Chambers and Partners.
The PDF edition of
Digital Healthcare 2024
is downloadable by clicking the “Read More / 阅读全文” at the end of this article.
此次《全球法律指南：数字健康2024》之中国篇由环球律师事务所
周磊
、
黄旭春
、
陈筝妮
、
王舒雯
、
韩越
、
代润霖
和
徐瑞苑
撰写。该指南结合了环球生命科学及医疗团队在该领域丰富的实务经验与研究成果，在数字医疗领域迅猛发展的背景下，对生命健康监管环境、非医疗监管机构、预防性医疗、医疗技术（可穿戴/植入式和可消化医疗技术）、医疗器械软件、远程医疗、医疗物联网、5G网络、人工智能、机器学习及所涉及的数据合规和监管合规等数据健康相关的问题进行深入解读，希望能够为企业在中国合法、合规地开展相关活动提供有价值、有深度、有层次的实务指引。如果您希望就本指南或就本指南所讨论的内容做进一步交流，敬请联系撰文作者。
The
Chambers Global Practice Guide: Digital Healthcare 2024 China (Law & Practice)
is written by legal professionals of Global Law Office,
Alan Zhou
,
Charlene
Huang
,
Jenny Chen
,
Stephanie Wang
,
Erin Han
,
Lynne Dai
, and
Ruiyuan Xu
. Against the backdrop of the rapid development of the digital healthcare, the guide provides in-depth analysis of major legal issues and topics related to digital healthcare, covering healthcare regulatory environment, non-healthcare regulatory agencies, preventative healthcare, healthcare technologies (wearables, implantable and digestible healthcare technologies), software as a medical device (SaMD), telehealth, the internet of medical things (IoMT), 5G networks, artificial intelligence (AI) and machine learning along with the analysis on relevant data compliance and regulatory compliance issues. By combining the rich experience of Global Law Office’s Life Sciences and Healthcare team, this chapter aims to provide a comprehensive perspective on the landscape of China’s digital healthcare sector, and practical guidelines for global and local pharmaceutical companies to conduct business activities in China in a legal and compliant manner. Should you have inquiries or comment regarding the publication, please feel free to contact the authors.
